1. Home
  2. FGI vs IMNN Comparison

FGI vs IMNN Comparison

Compare FGI & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FGI Industries Ltd.

FGI

FGI Industries Ltd.

N/A

Current Price

$3.93

Market Cap

7.7M

Sector

Industrials

ML Signal

N/A

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$3.22

Market Cap

11.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGI
IMNN
Founded
1987
1982
Country
United States
United States
Employees
420
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
11.0M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
FGI
IMNN
Price
$3.93
$3.22
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$182.61
AVG Volume (30 Days)
8.0K
17.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.80
N/A
Revenue Next Year
$6.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$0.37
52 Week High
$12.62
$9.32

Technical Indicators

Market Signals
Indicator
FGI
IMNN
Relative Strength Index (RSI) 37.05 43.18
Support Level $3.88 $3.03
Resistance Level $4.65 $3.16
Average True Range (ATR) 0.47 0.23
MACD -0.08 0.00
Stochastic Oscillator 32.89 23.73

Price Performance

Historical Comparison
FGI
IMNN

About FGI FGI Industries Ltd.

FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Share on Social Networks: